MedTrace Logo

Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12

NCT00000230 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with naltrexone.

Conditions

  • Opioid-Related Disorders

Interventions

DRUG

Buprenorphine

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Vermont

    lead OTHER

Principal Investigators

  • Warren Bickel, Ph.D. · University of Vermont

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000230 on ClinicalTrials.gov